ARIAD Pharmaceuticals (ARIA) 10-K2009 FY Annual report

Filed: 16 Mar 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: abstained, adapt, adult, adversel, advocating, af, affirmed, agreem, al, ALCL, analysi, API, app, arch, arketing, ary, ation, authoritative, banc, binding, bject, budgeting, cceptable, cease, ch, Chemgenex, chromosomal, collateral, Collier, commercia, Commissioner, considerat, constitute, convenience, correlation, covenant, criminal, cure, cycle, cytogenetic, debated, decided, decisio, deliverable, der, ding, DMC, doubt, driver, ear, ease, econd, educate, effort, eign, en, ent, ently, es, esponsible, execu, false, FDAAA, feature, fisc, formally, gave, glucose, gnized, hnology, imatinib, immaterial, inclu, includin, incomplete, ineffective, inst, insulin, investigat, irectly, largest, ll, lly, long, lun, lymphoblastic, mandatory, Medicaid, mg, midpoint, mifamurtide, milar, mill, minimal, mutation, myeloic, negative, negatively, ns, omacetaxine, orderly, osteopo, ou, outlicensing, overturned, owed, pan, perior, pervasive, Philadelphia, ponse, preliminary, properly, put, ransaction, rearrangement, reclassified, reco, recordkeeping, recurring, rehearing, remai, remittance, Removed, renegotiate, rese, Researc, resul, retrospectively, ri, rida, Roche, roval, Secretary, seizure, short, shutdown, si, sid, Smyth, ssue, st, sta, stoc, strong, su, suspension, Takeda, te, tec, ter, tha, ther, timated, tot, treatable, unfunded, ur, wait, waiver, warning, warrant, wel, wi

Removed: account, acid, activated, adjust, amounting, bench, broader, Bulletin, calculating, context, decline, devoted, dimerizer, EITF, enhance, entry, estimable, explicit, FIN, forfeiture, function, Genentech, Hedging, Hoffmann, IA, identification, Invalidation, LaRoche, leiomyosarcoma, lieu, liposarcoma, master, measuring, mix, November, nucleic, pathway, prevailed, prevalent, pronouncement, Publicly, reexamine, reexamining, reinvested, revalued, SAB, septic, shock, sublicense, Task, taxing, temporary, threshold, uneven, vote, Wyeth

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ARIA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of ARIAD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Annual Report on Form 10-K for the year ended December 31, 2009 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 16, 2010	/s/ Harvey J. Berger, M.D.
	Harvey J. Berger, M.D.
	Chairman of the Board of Directors,
	Chief Executive Officer and President


Dated: March 16, 2010	/s/ Edward M. Fitzgerald
	Edward M. Fitzgerald
	Senior Vice President,
	Chief Financial Officer and Treasurer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.